CRDF
Price
$2.39
Change
-$0.02 (-0.83%)
Updated
Aug 8 closing price
Capitalization
159M
80 days until earnings call
NAMS
Price
$25.31
Change
+$2.35 (+10.24%)
Updated
Aug 8 closing price
Capitalization
2.85B
98 days until earnings call
Interact to see
Advertisement

CRDF vs NAMS

Header iconCRDF vs NAMS Comparison
Open Charts CRDF vs NAMSBanner chart's image
Cardiff Oncology
Price$2.39
Change-$0.02 (-0.83%)
Volume$1.23M
Capitalization159M
NewAmsterdam Pharma
Price$25.31
Change+$2.35 (+10.24%)
Volume$1.88M
Capitalization2.85B
CRDF vs NAMS Comparison Chart in %
Loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDF vs. NAMS commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a StrongBuy and NAMS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (CRDF: $2.39 vs. NAMS: $25.31)
Brand notoriety: CRDF and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 56% vs. NAMS: 202%
Market capitalization -- CRDF: $159M vs. NAMS: $2.85B
CRDF [@Biotechnology] is valued at $159M. NAMS’s [@Biotechnology] market capitalization is $2.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, NAMS is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 6 TA indicator(s) are bullish while NAMS’s TA Score has 5 bullish TA indicator(s).

  • CRDF’s TA Score: 6 bullish, 5 bearish.
  • NAMS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than CRDF.

Price Growth

CRDF (@Biotechnology) experienced а -9.47% price change this week, while NAMS (@Biotechnology) price change was +18.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.11%. For the same industry, the average monthly price growth was +5.28%, and the average quarterly price growth was +13.38%.

Reported Earning Dates

CRDF is expected to report earnings on Oct 30, 2025.

NAMS is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+0.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($2.85B) has a higher market cap than CRDF($159M). NAMS YTD gains are higher at: -1.518 vs. CRDF (-44.931). CRDF has higher annual earnings (EBITDA): -53.95M vs. NAMS (-254.89M). NAMS has more cash in the bank: 808M vs. CRDF (71M). NAMS has less debt than CRDF: NAMS (389K) vs CRDF (1.19M). NAMS has higher revenues than CRDF: NAMS (47.1M) vs CRDF (545K).
CRDFNAMSCRDF / NAMS
Capitalization159M2.85B6%
EBITDA-53.95M-254.89M21%
Gain YTD-44.931-1.5182,961%
P/E RatioN/AN/A-
Revenue545K47.1M1%
Total Cash71M808M9%
Total Debt1.19M389K305%
FUNDAMENTALS RATINGS
CRDF: Fundamental Ratings
CRDF
OUTLOOK RATING
1..100
51
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRDFNAMS
RSI
ODDS (%)
Bullish Trend 4 days ago
62%
Bearish Trend 4 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
38%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
51%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
56%
Advances
ODDS (%)
Bullish Trend 26 days ago
87%
Bullish Trend 6 days ago
74%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 11 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
63%
Aroon
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CBSTF0.10N/A
+4.41%
THE CANNABIST COMPANY HOLDINGS INC.
EPIAF20.600.20
+0.99%
Epiroc Aktiebolag
HELOF0.08N/A
N/A
WINSHEAR GOLD CORP.
CUCSF0.56N/A
N/A
China Communications Services Corp., Ltd.
NRTZF11.18N/A
N/A
Noritz Corp.

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with NAMS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-0.83%
NAMS - CRDF
42%
Loosely correlated
+10.24%
QURE - CRDF
41%
Loosely correlated
-1.26%
MRVI - CRDF
40%
Loosely correlated
+8.64%
AKBLF - CRDF
37%
Loosely correlated
N/A
ABSI - CRDF
37%
Loosely correlated
-2.41%
More

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+10.24%
QURE - NAMS
56%
Loosely correlated
-1.26%
CRDF - NAMS
41%
Loosely correlated
-0.83%
IRON - NAMS
40%
Loosely correlated
+1.68%
BEAM - NAMS
39%
Loosely correlated
-1.34%
NRIX - NAMS
39%
Loosely correlated
-2.28%
More